摘要
目的研究安罗替尼联合深部热疗后线治疗晚期非小细胞肺癌(NSCLC)的近期疗效及远期生存,并评估安全性。方法选取60例一线治疗后病情进展的晚期NSCLC患者为研究对象,将入选患者随机纳入试验组和对照组,每组30例。2组患者均接受安罗替尼胶囊治疗。试验组在胸部区域增加深部热疗。比较2组患者客观反应率(ORR)、疾病控制率(DCR)及无进展生存时间(PFS)和不良反应发生情况。结果试验组和对照组ORR分别为26.7%和6.7%,DCR分别为90.0%和66.7%,2组患者中位PFS分别为9.0个月[95%CI(7.692~10.308)]和4.0个月[95%CI(2.211~9.789)],单因素生存分析提示安罗替尼是否联合热疗与PFS有关,差异均有统计学意义(P<0.05),但COX比例风险回归模型显示该因素并非PFS独立预后因素(P=0.051)。2组不良反应均为CTCAE 5.01~2级,无CTCAE5.03~5级不良反应出现。常见的不良反应包括手足皮肤反应,咳嗽、气短等。2组间治疗相关不良反应发生率差异无统计学意义(P>0.05)。结论在晚期NSCLC的后线治疗中,安罗替尼与深部热疗联合有助于提高疗效且不良反应可控。
Objective To understand the efficacy and safety of Anlotinib combined with deep-hyperthermia in treating advanced non-small cell lung cancer(NSCLC).Methods Sixty patients with advanced NSCLC with disease progression after first-line treatment were randomly assigned into the Trial group(30)and the Control group(30),and all patients were treated with Anlotinib capsules,those in the Trial group were additionally treated with deep-hyperthermia at the chest region.Objective response rate(ORR),disease control rate(DCR)and progression-free survival(PFS)and the occurrence of adverse reactions were included as comparisons between groups.Results ORR(26.7%vs 6.7%),DCR(90.0%vs 66.7%)in the Trial group were significantly higher than those in the Control group(P<0.05),and the median PFS(9.0 months[95%CI:7.692-10.308]vs 4.0 months[95%CI:2.211-9.789])was significantly longer(P<0.05).Univariate survival analyses suggested that the presence or absence of deep-hyperthermia was associated with PFS(P<0.05).While,the COX proportional risk regression model showed that this factor was not an independent prognostic factor for PFS(P=0.051).Adverse reactions in both groups were grades 1-2(Common Terminology Criteria for Adverse Events[CTCAE5.0]),and no grades 3-5 adverse reactions(CTCAE5.0)were observed.Common adverse reactions included skin reactions on hand and foot,cough,shortness of breath,etc.There was no statistical difference in the incidence of common adverse reactions between groups(P>0.05).Conclusion In the subsequent-line treatment regimens for advanced NSCLC,the combination of Amlotinib and deep-hyperthermia contributes to the improvement of the curve efficacy with manageable adverse effects.
作者
陈恕之
孙清
杭志强
周铮铮
王赛楠
马一薇
吴梓堇
徐凯
CHEN Shuzhi;SUN Qing;HANG Zhiqiang(Department of Oncology,Wuxi No.8 People's Hospital,Jiangsu,Wuxi 214000,China)
出处
《河北医药》
2025年第6期952-955,960,共5页
Hebei Medical Journal
基金
无锡市卫生健康委面上科研项目(编号:M202043)。
关键词
深部热疗
安罗替尼
NSCLC癌
不良反应
deep-hyperthermia
Anlotinib
non-small cell lung cancer
adverse reactions
